Stocks › GPCR
Structure Therapeutics Inc.
GPCR·Nasdaq·
United States·USD
United States·USD$27.47
-0.12 (-0.43%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
GPCR
Structure Therapeutics Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
GPCRS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of GPCR by members of U.S. Congress · 1 on record
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
 Thomas R CarperSenate · D · DE |
GPCRStructure Therapeutics Inc. · Stock |
Sale $1,001 - $15,000 |
Nov 2, 2023 | Oct 4, 2023 | Filing ↗ |
Whale Activity
Position changes in GPCR reported for 2026-09-30 by 1 tracked institutional filer
- Increased0
- New0
- Held0
- Decreased0
- Closed0
- No prior filing1
| Filer | Shares | Value | Change |
|---|---|---|---|
| Private Capital Advisors, Inc. | 29.8K | $931K | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by GPCR insiders, by quarter · Form 4
No open-market insider buys or sells in the last two years.
Recent Insider Transactions
73 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Lin XichenCHIEF SCIENTIFIC OFFICER | Conversion | −23.6K | $0.00 | $0 | Jun 25, 2026 | Form 4 ↗ |
| Lin XichenCHIEF SCIENTIFIC OFFICER | Option exercise | +23.6K | $0.34 | $8K | Jun 25, 2026 | Form 4 ↗ |
| Lang MatthewCOO & GC | Grant / award | +184.6K | $0.00 | $0 | Apr 15, 2026 | Form 4 ↗ |
| Coll Crespo BlasCHIEF MEDICAL OFFICER | Grant / award | +75.9K | $0.00 | $0 | Mar 19, 2026 | Form 4 ↗ |
| Ma YingliCHIEF TECHNOLOGY OFFICER | Grant / award | +32.5K | $0.00 | $0 | Mar 19, 2026 | Form 4 ↗ |
| Lin XichenCHIEF SCIENTIFIC OFFICER | Grant / award | +43.4K | $0.00 | $0 | Mar 19, 2026 | Form 4 ↗ |
| Yoon JunCHIEF FINANCIAL OFFICER | Grant / award | +104.1K | $0.00 | $0 | Mar 19, 2026 | Form 4 ↗ |
| Hall AshleyChief Development Officer | Grant / award | +47.7K | $0.00 | $0 | Mar 19, 2026 | Form 4 ↗ |
| Stevens Raymond CCHIEF EXECUTIVE OFFICER · Director | Grant / award | +260.2K | $0.00 | $0 | Mar 19, 2026 | Form 4 ↗ |
| Coll Crespo BlasCHIEF MEDICAL OFFICER | Tax withholding | −11.8K | $20.99 | $248K | Mar 3, 2026 | Form 4 ↗ |
| Ma YingliCHIEF TECHNOLOGY OFFICER | Tax withholding | −11.3K | $20.99 | $237K | Mar 3, 2026 | Form 4 ↗ |
| Lin XichenCHIEF SCIENTIFIC OFFICER | Tax withholding | −18.7K | $20.99 | $393K | Mar 3, 2026 | Form 4 ↗ |
| Yoon JunCHIEF FINANCIAL OFFICER | Tax withholding | −22.3K | $20.99 | $468K | Mar 3, 2026 | Form 4 ↗ |
| Hall AshleyChief Development Officer | Tax withholding | −4,836 | $20.99 | $102K | Mar 3, 2026 | Form 4 ↗ |
| Stevens Raymond CCHIEF EXECUTIVE OFFICER · Director | Tax withholding | −53.5K | $20.99 | $1.1M | Mar 3, 2026 | Form 4 ↗ |
| Coll Crespo BlasCHIEF MEDICAL OFFICER | Tax withholding | −8,106 | $7.74 | $63K | Sep 18, 2025 | Form 4 ↗ |
| Hall AshleyChief Development Officer | Tax withholding | −6,021 | $7.74 | $47K | Sep 18, 2025 | Form 4 ↗ |
| Ma YingliCHIEF TECHNOLOGY OFFICER | Tax withholding | −4,470 | $6.84 | $31K | Jul 1, 2025 | Form 4 ↗ |
| Lin XichenCHIEF SCIENTIFIC OFFICER | Tax withholding | −12.8K | $6.84 | $88K | Jul 1, 2025 | Form 4 ↗ |
| Coll Crespo BlasCHIEF MEDICAL OFFICER | Tax withholding | −1,434 | $6.84 | $10K | Jul 1, 2025 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding GPCR · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| Heritage Fund American Century Mutual Funds, Inc. | 967.4K | $46.5M | 0.87% | Jul 31, 2026 |
| Global Emerging Markets Fund Principal Funds, Inc | 625.8K | $30.1M | 0.40% | Jul 31, 2026 |
| Janus Henderson Global Life Sciences Fund Janus Investment Fund | 549.4K | $29.5M | 0.51% | Jun 30, 2026 |
| Fidelity Advisor Growth Opportunities Fund Fidelity Advisor Series I | 733.5K | $28.9M | 0.08% | May 31, 2026 |
| Fidelity Advisor Biotechnology Fund Fidelity Advisor Series VII | 527.9K | $25.4M | 1.15% | Jul 31, 2026 |
| Janus Henderson Triton Fund Janus Investment Fund | 467.1K | $25.1M | 0.42% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 419.4K | $22.5M | 0.19% | Jun 30, 2026 |
| iShares Biotechnology ETF iShares Trust | 414.3K | $22.2M | 0.24% | Jun 30, 2026 |
| Select Biotechnology Portfolio Fidelity Select Portfolios | 542.0K | $21.3M | 0.40% | May 31, 2026 |
| Select Health Care Portfolio Fidelity Select Portfolios | 540.0K | $21.2M | 0.37% | May 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list GPCR's shares (CUSIP 86366E106), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming Structure Therapeutics Inc. as client
No lobbying filings found naming Structure Therapeutics Inc. as the client.
Government Contracts
Federal awards to Structure Therapeutics Inc. · USAspending
No federal contract awards found for Structure Therapeutics Inc..
U.S. Patents
Recent USPTO applications naming Structure Therapeutics Inc.
No USPTO patent applications found for Structure Therapeutics Inc..
Annual Financials
From GPCR's 10-K filings · XBRL
No annual XBRL figures on record for GPCR. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in GPCR's price history.
Material Events (8-K)
Corporate events filed with the SEC
About Structure Therapeutics Inc.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersSOUTH SAN FRANCISCO, CA
IncorporatedE9
SEC CIK0001888886 ↗
Former namesShouTi Inc.